IRIS - Res&Arch Institutional Research Information System - Research & Archive

FANELLI, Carmine Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.212
EU - Europa 4.433
AS - Asia 4.089
SA - Sud America 694
Continente sconosciuto - Info sul continente non disponibili 341
AF - Africa 105
OC - Oceania 25
Totale 16.899
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.876
SG - Singapore 2.015
IT - Italia 688
IE - Irlanda 598
UA - Ucraina 590
CN - Cina 585
RU - Federazione Russa 584
BR - Brasile 537
SE - Svezia 529
HK - Hong Kong 417
DE - Germania 362
FR - Francia 337
VN - Vietnam 329
FI - Finlandia 224
GB - Regno Unito 166
BD - Bangladesh 164
CA - Canada 136
KR - Corea 96
IN - India 94
ES - Italia 88
TR - Turchia 74
AT - Austria 53
PL - Polonia 53
MX - Messico 52
AR - Argentina 50
JP - Giappone 45
ZA - Sudafrica 41
IQ - Iraq 40
NL - Olanda 38
CO - Colombia 32
UZ - Uzbekistan 32
CR - Costa Rica 27
GT - Guatemala 27
ID - Indonesia 26
PK - Pakistan 26
SA - Arabia Saudita 22
AU - Australia 21
CH - Svizzera 21
HN - Honduras 21
TT - Trinidad e Tobago 21
VE - Venezuela 19
PH - Filippine 18
CZ - Repubblica Ceca 17
EC - Ecuador 17
BE - Belgio 15
CW - ???statistics.table.value.countryCode.CW??? 15
MA - Marocco 15
GR - Grecia 13
JO - Giordania 12
MY - Malesia 12
PE - Perù 11
KE - Kenya 10
NP - Nepal 10
CL - Cile 9
IL - Israele 9
JM - Giamaica 9
LB - Libano 9
PR - Porto Rico 9
SV - El Salvador 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
LT - Lituania 8
RO - Romania 8
PY - Paraguay 7
TN - Tunisia 7
BO - Bolivia 6
NI - Nicaragua 6
AE - Emirati Arabi Uniti 5
BB - Barbados 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
EG - Egitto 5
OM - Oman 5
AL - Albania 4
DZ - Algeria 4
EE - Estonia 4
PS - Palestinian Territory 4
RS - Serbia 4
TH - Thailandia 4
UY - Uruguay 4
BH - Bahrain 3
CI - Costa d'Avorio 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
HR - Croazia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
TG - Togo 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
BY - Bielorussia 2
GH - Ghana 2
GP - Guadalupe 2
HU - Ungheria 2
IM - Isola di Man 2
KG - Kirghizistan 2
Totale 16.542
Salva come PNG Salva come JPEG
Città #
Singapore 1.414
San Jose 738
Chandler 684
Dublin 599
Ashburn 579
Hong Kong 410
San Mateo 346
Boardman 279
Jacksonville 272
Santa Clara 272
Council Bluffs 219
Altamura 192
Princeton 175
Medford 172
Moscow 164
Lauterbourg 155
Beijing 152
Wilmington 144
Lawrence 129
New York 127
Los Angeles 121
Perugia 121
Munich 117
Seoul 93
Des Moines 89
Ann Arbor 88
Dong Ket 85
Andover 78
Helsinki 76
Ho Chi Minh City 70
Rome 53
Saint Petersburg 53
São Paulo 53
The Dalles 52
Frankfurt am Main 51
Valencia 50
Hanoi 46
Dallas 43
North Bergen 43
Brooklyn 41
Piscataway 41
Chicago 39
Tokyo 38
Montreal 36
Falls Church 35
Orem 32
Warsaw 31
Izmir 28
Milan 28
Woodbridge 27
Stockholm 26
Toronto 26
Norwalk 25
Nuremberg 25
Phoenix 24
San Francisco 24
Tashkent 23
Vienna 23
Atlanta 22
Denver 21
Amsterdam 20
Buffalo 20
Turku 20
San José 19
London 18
Fremont 17
Rio de Janeiro 17
Baghdad 16
Guatemala City 16
Istanbul 16
Shanghai 16
Amelia 15
Ankara 15
Da Nang 15
Mexico City 15
San Paolo di Civitate 15
Willemstad 15
Charlotte 14
Falkenstein 14
Houston 14
Redmond 14
Brussels 13
Johannesburg 13
Amman 12
Haiphong 12
Boston 11
Brasília 11
Brno 11
Philadelphia 11
Auburn Hills 10
Belo Horizonte 10
Chennai 10
Poplar 10
Porto Alegre 10
Roubaix 10
San Pedro Sula 10
Buenos Aires 9
Campinas 9
Chaguanas 9
Columbus 9
Totale 9.760
Salva come PNG Salva come JPEG
Nome #
Adrenaline vs glucagon in the primacy of glucose counterregulation 182
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 173
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 173
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 168
Hypoglycemia 159
Physical activity habits and well-being among 6-year-old children: The “improving umbrian kids’ healthy lifestyle”, an uncontrolled pilot study project 157
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 154
An intensive lifestyle intervention in children with attention-deficit/hyperactivity disorder 152
Physical activity level and mediterranean diet adherence evaluation in older people - observational, uncontrolled, pilot study 147
Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes 146
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 145
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 144
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 143
18. Insulin required for prandial ghrelin suppression in humans 141
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage 134
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 134
A novel surrogate index for hepatic insulin resistance. 133
Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes 131
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 131
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 130
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 129
Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia 128
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 128
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 128
Effects of an Intensive Lifestyle Intervention to Treat Overweight/Obese Children and Adolescents 126
Cognitive function in hypoglycaemia 125
Ipoglicemia: implicazioni cliniche e impatto sulla salute 123
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 122
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 120
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 119
Insulin is required for prandial ghrelin suppression in humans 119
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 118
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review 117
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 117
Nocturnal blood glucose control in type I diabetes mellitus. 117
Evaluation of maximum oxygen consumption in obese adolescents before and after a multidisciplinary lifestyle intervention 117
IMPACT OF NOCTURNAL HYPOGLYCEMIA ON HYPOGLYCEMIC COGNITIVE DYSFUNCTION IN TYPE 1 DIABETES 116
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 116
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 115
Are three months multidisciplinary lifestyle intervention enough to get benefits on blood pressure in overweight/obese adults ? 115
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 114
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 112
Effects of a supervised nordic walking program on obese adults with and without type 2 diabetes: The C.U.R.I.A.Mo. Centre experience 112
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 111
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 110
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs 110
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 108
Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes 108
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 107
Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. 107
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 107
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 107
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 107
Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. 106
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 105
Early improvement of glucose tolerance after ileal transposition in a nonobese Type 2 diabetes rat model. 105
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules 105
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 105
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 105
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 104
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 103
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 102
Impact of BMI, Physical Activity, and Sitting Time Levels on Health-Related Outcomes in a Group of Overweight and Obese Adults with and without Type 2 Diabetes 102
Body composition and common carotid artery remodeling in a healthy population 101
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 101
Glucagon: the effects of its excess and deficiency on insulin action 100
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 100
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 99
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 98
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 96
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 96
The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study 95
Circulatin ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 95
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 95
Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes 95
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 94
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 94
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 93
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. 92
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 92
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 91
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. 91
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 91
Ipoglicemia: cause e prevenzione 90
"Strength gains in different age groups of overweight/obese adults: A pilot uncontrolled study" 89
Counterregulatory responses in CSII 89
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 89
Obesity and carotid artery remodeling 89
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 88
Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. 88
A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes 88
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 88
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 87
Is physical activity a necessary element during Italian coronavirus disease emergency? Yes or no debate 86
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 84
Reversibility of unawareness of hypoglycemia in patients with insulinomas. 83
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 81
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement. 81
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 81
Responses to hypoglycemia in diabetic autonomic neuropathy. 81
Totale 11.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022907 0 0 0 0 34 20 20 407 16 32 137 241
2022/20232.310 184 465 31 191 170 287 5 95 788 3 67 24
2023/2024982 54 105 43 33 8 8 195 14 77 39 185 221
2024/20252.340 36 230 81 126 366 65 59 182 513 167 304 211
2025/20265.525 360 325 266 603 779 408 1.004 280 738 414 179 169
2026/20272.019 193 175 346 1.165 140 0 0 0 0 0 0 0
Totale 16.899